EMA Recommends Extension of Indications for Acalabrutinib to Include the Treatment for Patients with MCL By Ogkologos - April 3, 2025 696 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR ESMO Raises Key Issues on Cancer Prevention and Care at the WHO Executive Board Meeting Noninferiority of OS with 3 Months Compared to 6 Months of Adjuvant Chemotherapy for Patients with High-Risk Stage III Colorectal Cancer Patient Guide on Bone Health in Cancer Now Available Also in French MOST POPULAR Adding Atezolizumab to First-Line Bevacizumab Plus Platinum Regimen Improves Survival in... December 12, 2023 Suzanne Somers Discusses Her Cancer Diagnosis And Thinking Of Her ‘Mortality’ January 6, 2020 FDA Grants Accelerated Approval to Ponatinib with Chemotherapy for Newly Diagnosed... March 29, 2024 FDA Approves Trastuzumab Deruxtecan for Any HER2-Positive Solid Cancer May 3, 2024 Load more HOT NEWS Cancer waiting times: Latest updates and analysis How to Find the Right Hospice Care Program for You or... Asciminib Shows Superior Efficacy Over Investigator-Selected TKIs and Imatinib in Patients... Significant Benefits of Nivolumab Plus Cabozantinib Over Sunitinib in Previously Untreated...
